Alkermes ALKS
NASDAQ ALKS
$41.75 +1.21 (+2.98%)
At close: Oct 2, 2026 · 4:00 PM EDT

Alkermes (ALKS) Gains from Sales and Divestitures (2014 - 2015)

Updated

Alkermes' Gains from Sales and Divestitures was -$301,000 in Q4 2015, compared with $28.16 million a year earlier.

Analysis

Alkermes (ALKS) Gains from Sales and Divestitures (2014 - 2015) Analysis & Trends

For FY2015, Gains from Sales and Divestitures at Alkermes came in at $9.64 million, down 76.0% from FY2014.

  • In earlier years, Gains from Sales and Divestitures was $40.1 million in FY2014 and -$129,000 in FY2013.
  • The Q4 2015 figure marks the lowest quarterly Gains from Sales and Divestitures since Q2 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Alkermes 6.99 Bn 4.13 Bn 397.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 -301,000.00
Sep 30, 2015 26,000.00
Jun 30, 2015 9.91 Mn
Dec 31, 2014 28.16 Mn
Sep 30, 2014 -218,000.00
API Access

Alkermes Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ALKS&period=max&api_key=YOUR_API_KEY